EP4031122A4 - Formulations de comprimés effervescents comprenant de la dapagliflozine et de la metformine - Google Patents
Formulations de comprimés effervescents comprenant de la dapagliflozine et de la metformine Download PDFInfo
- Publication number
- EP4031122A4 EP4031122A4 EP20866500.0A EP20866500A EP4031122A4 EP 4031122 A4 EP4031122 A4 EP 4031122A4 EP 20866500 A EP20866500 A EP 20866500A EP 4031122 A4 EP4031122 A4 EP 4031122A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- dapagliflozin
- metformin
- effervescent tablet
- tablet formulations
- formulations
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- JVHXJTBJCFBINQ-ADAARDCZSA-N Dapagliflozin Chemical compound C1=CC(OCC)=CC=C1CC1=CC([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=CC=C1Cl JVHXJTBJCFBINQ-ADAARDCZSA-N 0.000 title 1
- 229960003834 dapagliflozin Drugs 0.000 title 1
- 239000007938 effervescent tablet Substances 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 title 1
- 229960003105 metformin Drugs 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TR2019/14043A TR201914043A1 (tr) | 2019-09-16 | 2019-09-16 | Dapagli̇flozi̇n ve metformi̇n i̇çeren efervesan tablet formülasyonlari |
PCT/TR2020/050687 WO2021054912A1 (fr) | 2019-09-16 | 2020-08-05 | Formulations de comprimés effervescents comprenant de la dapagliflozine et de la metformine |
Publications (2)
Publication Number | Publication Date |
---|---|
EP4031122A1 EP4031122A1 (fr) | 2022-07-27 |
EP4031122A4 true EP4031122A4 (fr) | 2023-08-30 |
Family
ID=74883168
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP20866500.0A Pending EP4031122A4 (fr) | 2019-09-16 | 2020-08-05 | Formulations de comprimés effervescents comprenant de la dapagliflozine et de la metformine |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP4031122A4 (fr) |
TR (1) | TR201914043A1 (fr) |
WO (1) | WO2021054912A1 (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4079296A1 (fr) * | 2021-04-21 | 2022-10-26 | Sanovel Ilac Sanayi Ve Ticaret A.S. | Formulation de comprimé bicouche comprenant de la dapagliflozine amorphe et de la metformine |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150238421A1 (en) * | 2009-11-13 | 2015-08-27 | Astrazeneca Ab | Bilayer Tablet Formulations |
WO2017098481A1 (fr) * | 2015-12-12 | 2017-06-15 | Steerlife India Private Limited | Compositions effervescentes de metformine et leurs procédés de préparation |
WO2018185669A1 (fr) * | 2017-04-07 | 2018-10-11 | Zenvision Pharma Llp | Compositions effervescentes comprenant de la saxagliptine ou un sel de celle-ci |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007038979A1 (fr) * | 2005-09-22 | 2007-04-12 | Swissco Development Ag | Composition effervescente de metformine et comprimés et granules fabriqués à partir de cette composition |
EP2809311A1 (fr) * | 2012-01-31 | 2014-12-10 | Mahmut Bilgic | Formulations de comprimés effervescents contenant la combinaison voglibose et metformine |
-
2019
- 2019-09-16 TR TR2019/14043A patent/TR201914043A1/tr unknown
-
2020
- 2020-08-05 WO PCT/TR2020/050687 patent/WO2021054912A1/fr unknown
- 2020-08-05 EP EP20866500.0A patent/EP4031122A4/fr active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150238421A1 (en) * | 2009-11-13 | 2015-08-27 | Astrazeneca Ab | Bilayer Tablet Formulations |
WO2017098481A1 (fr) * | 2015-12-12 | 2017-06-15 | Steerlife India Private Limited | Compositions effervescentes de metformine et leurs procédés de préparation |
WO2018185669A1 (fr) * | 2017-04-07 | 2018-10-11 | Zenvision Pharma Llp | Compositions effervescentes comprenant de la saxagliptine ou un sel de celle-ci |
Non-Patent Citations (1)
Title |
---|
See also references of WO2021054912A1 * |
Also Published As
Publication number | Publication date |
---|---|
TR201914043A1 (tr) | 2021-04-21 |
WO2021054912A1 (fr) | 2021-03-25 |
EP4031122A1 (fr) | 2022-07-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP4051246A4 (fr) | Formulations de comprimés bicouches comprenant de la dapagliflozine et de la metformine | |
IL284835A (en) | Pharmaceutical combination containing TNO155 and ribociclib | |
EP4045480A4 (fr) | Formulations pharmaceutiques | |
EP3938369A4 (fr) | Inhibiteurs de tyk2 et leurs utilisations | |
EP3914357A4 (fr) | Inhibiteurs de tyk2 et leurs utilisations | |
EP3904351A4 (fr) | Inhibiteur de fak et combinaison de médicaments associée | |
EP3985014A4 (fr) | Peptides antimicrobiens dérivés de romo1 et variants de ceux-ci | |
EP4149470A4 (fr) | Formulations pharmaceutiques et leurs utilisations | |
EP3981769A4 (fr) | Composé de pyrrolopyrimidine et son utilisation | |
EP3999183A4 (fr) | Composé présentant une activité inhibitrice de kdm5 et utilisation pharmaceutique associée | |
EP3919498A4 (fr) | Dérivé de pyrrolopyrimidine et son utilisation | |
EP3851121A4 (fr) | Composition pharmaceutique contenant un anticorps monoclonal anti-il-33 humain | |
EP3784672A4 (fr) | Formulations de comprimés comprenant de la metformine et de la sitagliptine | |
EP3962528A4 (fr) | Combinaisons thérapeutiques comprenant des immunoconjugués anti-cd123 | |
EP3976014A4 (fr) | Combinaison comprenant de l'alogliptine et de la metformine | |
EP4112047A4 (fr) | Comprimé oral complexe comprenant de la sitagliptine, de la dapagliflozine et de la metformine | |
EP4031122A4 (fr) | Formulations de comprimés effervescents comprenant de la dapagliflozine et de la metformine | |
EP4070114A4 (fr) | Puces à flavivirus et leur utilisation | |
EP3999056A4 (fr) | Combinaison pharmaceutique et son utilisation | |
EP4014999A4 (fr) | Produit de combinaison contenant un composé de limonine et un médicament à base de sulfonylurée | |
EP4048276A4 (fr) | Formulations pharmaceutiques solides comprenant du ticagrelor | |
EP4058025A4 (fr) | Compositions pharmaceutiques comprenant du ticagrelor | |
EP3694519A4 (fr) | Combinaison pharmaceutique comprenant de la dapoxétine et de la phosphodiestérase de type 5 | |
EP4069233A4 (fr) | Association pharmaceutique et son utilisation | |
EP4129283A4 (fr) | Association pharmaceutique et son utilisation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20220315 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230708 |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20230727 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 3/10 20060101ALI20230721BHEP Ipc: A61K 9/20 20060101ALI20230721BHEP Ipc: A61K 31/351 20060101ALI20230721BHEP Ipc: A61K 31/155 20060101AFI20230721BHEP |